Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (782)	3/15/2000 6:20:00 PM
From: david james	Respond to of 1298

Cell Genesys Chairman & CEO: Diverse Revenue Bases and Products Key to Success By: Lisa Hayden Sector: Biotechnology Roseville, CA - March 13, 2000 - Dr. Stephen Sherwin, Chairman and CEO of Cell Genesys (NASDAQ:CEGE), told attendees on March 11th at InformedInvestors.com's 8th Bay Area Biotechnology Stocks Forum in Santa Clara, CA, that careful management of unique, diversified assets and product lines has been key to his company's financial success. "I think we're pretty unusual given the kinds of assets in the business," Dr. Sherwin said, answering a question about shareholder value. He highlighted company assets, including "the core business -- our products and technology. We have our holdings in Abgenix (NASDAQ: ABGX). We have the gene activation licensing program... It not only gives you different ways to win, but it gives you a floor." Cell Genesys, of Foster City, CA, is working to develop and commercialize gene therapies to treat major, life-threatening diseases including cancer and AIDS. The company is conducting Phase I/II human clinical trials for its GVAX(TM) cancer vaccines in prostate cancer and lung cancer, and the company's AIDS gene therapy is in Phase II human clinical testing. Preclinical stage programs include gene therapy for cancer, hemophilia, Parkinson's disease, and cardiovascular disorders. The company has more than 220 issued patents and over 330 pending. Dr. Sherwin said that the GVAX vaccine has shown good results in clinical tests. He said the vaccine contains genetically modified cells that help tumor cells generate an immune response. "That immune response, in effect, becomes a way of treating cancer. So this is a treatment vaccine not a way of preventing cancer." Hemophilia treatments also present opportunities for Cell Genesys, and Dr. Sherwin noted that initial preclinical data have been positive and "are behind our desire to move this program into clinical trials. And we know that this is a competitive area but we're pretty pleased with the competitive advantages that we have and the fact that we have two gene delivery systems to apply, over 90 patent filings pertaining to these systems, and available manufacturing processes that are already in place." Cell Genesys hopes to initiate clinical trials in 2001. Cell Genesys also has a licensing program for gene activation technology. Aventis Pharmaceuticals (NYSE:AVE) recently licensed the company's technology for the development of gene-activated erythropoietin (EPO) and a second undisclosed protein. Cell Genesys has resources of over $1 billion in financial assets, including $250 million in cash and the value of its 12% ownership of former subsidiary Abgenix. Dr. Sherwin declared that, "in my almost 18 years in biotechnology, I have never encountered these circumstances and I can assure you we intend to make the most of these opportunities and create as much shareholder value as possible." informedinvestors.com